AVROBIO, a leader in lentiviral-based gene therapies, is a clinical stage company developing disruptive therapies that have the potential to transform patients’ lives in a single dose.
Gene therapy involves the transplantation of normal genes into cells in order to correct genetic disorders. Gene therapy uses a vector to carry and deliver a working copy of a gene to the body’s cells. AVROBIO’s plato™ is designed to target underlying genetic disease by restoring normal gene function and enzyme production.
AVROBIO is conducting a study to evaluate the safety and efficacy of gene therapy for Type 1 Gaucher patients in Australia & New Zealand. All travel will be reimbursed. For more information about AVROBIO please visit www.avrobio.com
If you or someone you know is a type 1 Gaucher patient between the ages of 16 and 35 and are interested in participating, please contact us and we’ll connect you for more information.
As always we encourage everyone to discuss all medical issues with their clinicians .